PineBridge Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

PineBridge Investments’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$89.8M	Buy	271,419 +171,220	+171%	+$58.3M	0.76%	27
2025 Q4	$39.8M	Buy	100,199 +99,542	+15,151%	+$44.1M	0.29%	67
2025 Q3	$300K	Buy	+657	New	+$268K	﹤0.01%	516
2024 Q4	–	Sell	-8,222	Closed	-$2.26M	–	710
2024 Q3	$2.26M	Sell	8,222 -688	-8%	-$179K	0.02%	440
2024 Q2	$2.17M	Sell	8,910 -4,442	-33%	-$701K	0.02%	377
2024 Q1	$1.99M	Buy	13,352 +3,171	+31%	+$529K	0.02%	413
2023 Q4	$1.95M	Buy	10,181 +2,805	+38%	+$478K	0.02%	376
2023 Q3	$1.31M	Buy	+7,376	New	+$1.41M	0.01%	416

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PineBridge Investments's ALNY Position: Q1 2026 in Review

PineBridge Investments increased its Alnylam Pharmaceuticals (ALNY) stake by 171% in Q1 2026, buying an estimated $58.3M and bringing the position to 271,419 shares worth $89.8M. The position accounts for 0.76% of the portfolio, ranked #27.

PineBridge Investments first reported a position in ALNY in Q3 2023 and has held it in 8 quarters since. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

PineBridge Investments held 271,419 shares of Alnylam Pharmaceuticals worth $89.8M as of Q1 2026.
PineBridge Investments bought 171,220 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $58.3M.
Alnylam Pharmaceuticals made up 0.76% of PineBridge Investments's portfolio in Q1 2026, its #27 holding.
PineBridge Investments first reported a position in Alnylam Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on PineBridge Investments's 13F filing for Q1 2026, filed 14 May 2026.